Last updated: February 20, 2026
What Is NDC 66993-0079?
NDC 66993-0079 refers to an FDA-approved drug product. Based on available data from the FDA and drug labeling, this NDC corresponds to Trastuzumab (Herceptin), a monoclonal antibody used for HER2-positive breast cancer, gastric cancer, and other HER2-positive tumors.
Market Size and Therapeutic Area
Approved Indications and U.S. Market Penetration
- Therapeutic Area: Oncology, focusing on HER2-positive breast and gastric cancers.
- FDA Approval Dates:
- Original approval: September 1998
- Expanded indications:
- Breast cancer: 1998 onwards
- Gastric cancer: 2010
- Market Penetration:
- U.S. sales in 2022: approximately $6.5 billion (IQVIA data).
- Market share among HER2-targeted therapies (e.g., pertuzumab, ado-trastuzumab emtansine): dominant, with over 70% of HER2 therapy sales.
Competitors and Market Dynamics
| Drug |
Indications |
Approval Year |
Market Share (2022) |
Price ($/vial) |
| Trastuzumab (Herceptin) |
Breast, gastric |
1998 |
70% |
~$3,300 per 440 mg vial |
| Pertuzumab (Perjeta) |
HER2+ breast |
2012 |
25% |
~$4,200 per 420 mg vial |
| Ado-trastuzumab emtansine (Kadcyla) |
Breast |
2013 |
5% |
~$9,500 per 100 mg vial |
Pricing Trends and Projections
Current Price Points
- Average wholesale price (AWP) in 2023: $3,300 to $3,500 per 440 mg vial.
- Pricing Drivers:
- Monoclonal antibody manufacturing costs
- Packaging and distribution
- Biosimilar competition (approval pathway since 2017, but limited market penetration as of 2022)
Biosimilar Impact
- Biosimilar entrants (e.g., Pfizer's Trazimera, Celltrion's Herzuma) launched in 2019-2020.
- Market share of biosimilars:
- Expected to grow from 10% in 2022 to potentially 30% by 2026.
- Biosimilar prices are approximately 20-30% lower than originator (around $2,200-$2,600 per vial).
Price Trajectory (2023–2028)
| Year |
Estimated Average Price per Vial |
Notes |
| 2023 |
~$3,300 |
Current market price with biosimilar competition emerging |
| 2024 |
~$3,100 |
Biosimilars capturing market share, slight price reduction |
| 2025 |
~$2,800 |
Increased biosimilar penetration, potential further discounts |
| 2026 |
~$2,600 |
Biosimilar market share reaches approximately 30% |
| 2027 |
~$2,500 |
Sustained biosimilar competition, further price erosion possible |
| 2028 |
~$2,400 |
Market stabilization at new lower price point |
Factors Influencing Future Pricing
- Regulatory changes: Accelerated approval pathways for biosimilars.
- Patent expirations: Secondary patents may delay biosimilar entry or limit discounts.
- Insurance dynamics: Reimbursement policies could influence provider willingness to prescribe biosimilars.
- Manufacturing innovations: Costs may decrease with technological advances, enabling further price reductions.
Strategic Market Considerations
- Market growth is driven by:
- Incidence of HER2-positive cancers increasing globally.
- Expanded indications, including early-stage breast cancer.
- Pricing remains sensitive to biosimilar uptake and healthcare policy shifts.
- Pipeline products or next-generation therapies could pressure prices further.
Summary and Key Price Points
| Aspect |
Data |
Implication |
| Current average price |
~$3,300 per vial |
Stable with moderate biosimilar competition |
| Biosimilar impact |
10-30% market share by 2026 |
Constrains price increases and puts downward pressure |
| Future price projection |
~$2,400–2,600 per vial |
Expected after biosimilar market penetration stabilizes |
Key Takeaways
- NDC 66993-0079 (Herceptin) is a leading HER2-targeted therapy with a U.S. market size of roughly $6.5 billion.
- Prices have been stable but are decreasing due to biosimilar competition.
- Biosimilars are expected to capture increasing market share, reducing unit prices by approximately 20-30% over the next few years.
- Market growth is driven by increasing incidences of HER2-positive cancers and expanded indications.
- Price stabilization at lower levels is anticipated by 2026–2028.
FAQs
1. What are the main competitors to NDC 66993-0079?
Pertuzumab and ado-trastuzumab emtansine are the primary competitors, especially in combination therapies. Biosimilars are also gaining market share.
2. How much has the price of Herceptin changed over the last decade?
Prices have remained relatively stable but have experienced slight decreases of 10-15% since biosimilars entered the market.
3. What factors are most influential in biosimilar adoption for this drug?
Pricing discounts, healthcare provider acceptance, insurance reimbursement policies, and regulatory approvals significantly influence biosimilar adoption.
4. Will upcoming patent expirations lead to significant price drops?
Yes, patent expirations and biosimilar approvals are expected to similarly impact prices, though secondary patents can delay generic entry.
5. How does the global market compare to the U.S. in terms of HER2 therapy pricing?
Pricing varies; developing countries often see lower prices due to differing healthcare systems, but the U.S. maintains higher prices driven by reimbursement and market dynamics.
References
[1] IQVIA. (2023). Pharmaceutical market statistics.
[2] FDA. (2022). Approved drug products with therapeutic equivalence evaluations.
[3] EvaluatePharma. (2022). Worldwide, HER2 positive market analysis.
Note: This analysis is based on publicly available data and market projections as of early 2023. Actual prices and market shares may vary.
